Identification of nanopeptide from HTLV-III, ARV-2 and LAVBRU envelope gp120 determining binding to T4 cell surface protein. NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Identification of nanopeptide from HTLV-III, ARV-2 and LAVBRU envelope gp120 determining binding to T4 cell surface protein.

Cancer Biochem Biophys. 1988 Nov;10(2):91-106. Unique Identifier : AIDSLINE MED/89303784
Veljkovic V; Metlas R; Laboratory for Multidisciplinary Research RA 180/2, Boris Kidric; Institute, Beograd, Yugoslavia.

Abstract: The information contained in the primary structure of HIV envelope gp120 determining its biological activity, was analyzed by the use of the informational spectrum method. The parameter determining the interaction between gp120 and T4 cell-surface protein was defined. On the basis of this data in the conserved region of gp120 from HTLV-III, LAVBRU and ARV-2, a nanopeptide NAKTIIVQL was identified as a potential binding domain which could be used as a component of an effective therapeutic agent or as a vaccine component.
Keywords: Amino Acid Sequence Antigens, Surface/*METABOLISM Cell Membrane HIV Molecular Sequence Data Oligopeptides/GENETICS/*METABOLISM Protein Binding Receptors, Virus/*METABOLISM Retroviridae Proteins/*GENETICS Sequence Homology, Nucleic Acid Structure-Activity Relationship Viral Envelope Proteins/*GENETICS JOURNAL ARTICLE

KWDaminoacidsequenceantigens,surface/KWDmetabolismcellmembranehivmolecularsequencedataoligopeptides/genetics/KWDmetabolismproteinbindingreceptors,virus/KWDmetabolismretroviridaeproteins/KWDgeneticssequencehomology,nucleicacidstructure-activityrelationshipviralenvelopeproteins/KWDgeneticsjournalarticle
891030
M89A0591

Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .